Gilder Gagnon Howe & Co. LLC Sells 1,402 Shares of HealthEquity, Inc. (NASDAQ:HQY)
Gilder Gagnon Howe & Co. LLC cut its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 1.6% during the second quarter, Holdings Channel reports. The institutional investor owned 84,387 shares of the company’s stock after selling 1,402 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in HealthEquity were worth $4,205,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its position in HealthEquity by 157,852.9% in the first quarter. BlackRock Inc. now owns 5,589,953 shares of the company’s stock worth $237,293,000 after buying an additional 5,586,414 shares in the last quarter. Vanguard Group Inc. raised its position in HealthEquity by 6.2% in the first quarter. Vanguard Group Inc. now owns 4,115,237 shares of the company’s stock worth $174,691,000 after buying an additional 240,136 shares in the last quarter. FMR LLC raised its position in HealthEquity by 23.0% in the first quarter. FMR LLC now owns 1,535,422 shares of the company’s stock worth $65,179,000 after buying an additional 286,981 shares in the last quarter. Stephens Investment Management Group LLC raised its position in HealthEquity by 4.5% in the first quarter. Stephens Investment Management Group LLC now owns 1,218,220 shares of the company’s stock worth $51,713,000 after buying an additional 52,626 shares in the last quarter. Finally, State Street Corp raised its position in HealthEquity by 8.6% in the first quarter. State Street Corp now owns 1,057,823 shares of the company’s stock worth $44,901,000 after buying an additional 83,973 shares in the last quarter. Institutional investors and hedge funds own 90.26% of the company’s stock.
HealthEquity, Inc. (NASDAQ:HQY) opened at 47.48 on Thursday. The stock has a market capitalization of $2.85 billion, a price-to-earnings ratio of 89.25 and a beta of 1.73. The stock’s 50 day moving average is $49.07 and its 200-day moving average is $46.15. HealthEquity, Inc. has a 52-week low of $28.33 and a 52-week high of $54.95.
HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Tuesday, June 6th. The company reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. HealthEquity had a net margin of 17.04% and a return on equity of 11.61%. The business had revenue of $55.40 million for the quarter, compared to the consensus estimate of $54.77 million. During the same period last year, the firm earned $0.15 earnings per share. The company’s quarterly revenue was up 25.9% on a year-over-year basis. Equities research analysts anticipate that HealthEquity, Inc. will post $0.58 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/gilder-gagnon-howe-co-llc-sells-1402-shares-of-healthequity-inc-nasdaqhqy/1468080.html.
HQY has been the subject of a number of recent research reports. BidaskClub lowered shares of HealthEquity from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded shares of HealthEquity from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Wednesday, July 12th. TheStreet upgraded shares of HealthEquity from a “c” rating to a “b” rating in a research note on Monday, July 31st. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $61.00 price objective (up from $57.00) on shares of HealthEquity in a research note on Monday, June 12th. Finally, Chardan Capital lifted their price objective on shares of HealthEquity from $53.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $50.22.
In other news, Director Frank Medici sold 210,906 shares of the stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $52.03, for a total value of $10,973,439.18. Following the completion of the sale, the director now directly owns 6,381 shares of the company’s stock, valued at $332,003.43. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Stephen Neeleman sold 8,500 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $50.83, for a total transaction of $432,055.00. Following the completion of the sale, the insider now directly owns 1,000 shares of the company’s stock, valued at $50,830. The disclosure for this sale can be found here. Insiders sold 2,440,821 shares of company stock worth $125,325,268 over the last quarter. Insiders own 29.00% of the company’s stock.
HealthEquity Company Profile
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY).
Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.